Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886, (Youri I Pavlov, personal communication) Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886 Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886 Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886
Youri I Pavlov, personal communication
Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886
Youri I Pavlov, personal communication
Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886
Pavlov YI, et al. In vivo consequences of putative active site mutations in yeast DNA polymerases alpha, epsilon, delta, and zeta. Genetics 159: 47-64, 2001. PubMed: 11560886
